Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024
Details : Dasynoc (dasatinib) is an amorphous solid dispersion form & innovative protein kinase inhibitor, small molecule drug. It is being developed for the treatment of chronic myeloid leukemia.
Product Name : Dasynoc
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
Details : Xspray Pharma's lead product XS004 (dasatinib) is being evaluated in the late-stage clinical trial studies for treating patients suffering from chronic myeloid leukemia.
Product Name : Dasynoc
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2024
Xspray Pharma’s XS003 Study Shows Lower Dose Bioavailability vs. Tasigna
Details : XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2024
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2023
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sorafenib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Sorafenib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Under the agreement, EVERSANA will support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc (dasatinib) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL).
Product Name : Dasynoc
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 24, 2023
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : QPS Bioserve India
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : QPS Bioserve India
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2022
Lead Product(s) : Dasatinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Axis Clinicals Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xspray Pharma Reports Positive Results From a Study with Dasatinib During Omeprazole Treatment
Details : Xspray Pharma has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric p...
Product Name : Dasynoc
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2020
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XS003
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Comparison of XS003 and Tasigna
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2014
Lead Product(s) : XS003
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable